Please login to the form below

Not currently logged in
Email:
Password:

Eisai sets up new pharmaceutical marketing subsidiary in Belgium

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Japanese pharmaceutical company, Eisai, has established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium.

Eisai SA/NV is owned by Eisai Europe and will serve as the regional sales centre for Benelux countries, the sixth largest market in the EU. The subsidiary will begin marketing activities in the region, focusing on the anti-epileptic drugs Zonegran (zonisamide) and Inovelon (rufinamide). It will also start to market the non-opioid severe chronic infused pain drug Prialt (ziconotide), while also co-promoting Alzheimer's disease treatment Aricept (donepezil) in Belgium and Luxembourg with its partner, Pfizer.

Eisai says it will further expand its business operations across the EU and will undertake independent marketing activities by using its own sales and marketing personnel, tailored for each county.

Eisai SA/NV is Eisai's ninth marketing subsidiary in the EU region, bringing the total number of countries where Eisai has sales and marketing operations through its own distribution channels to 17. These include the UK, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Belgium, Netherlands and Luxembourg.



28th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics